To determine the efficacy and safety of micafungin (FK463) versus fluconazole (Diflucan) in treating patients with invasive candidiasis or candidaemia

Micafungin (a new class of antifungal drugs) is compared to fluconazole (current standard treatment) in the treatment of patients with serious fungal infections (invasive candidiasis and candidemia) to determine its efficacy and safety. Patients, both male and female, aged over 16 and with confirmed disease by the doctor could be recruited and evaluated.

Inclusion Criteria:

• Patients with a confirmed diagnosis of candidemia and invasive candidiasis
• Patients could be newly diagnosed with candidiasis who received no more than 48 hours of prior systemic antifungal therapy
• Inpatients aged 16 and above

Exclusion Criteria:

• Patients with serious invasive candidiasis whose prognoses are considered to be poor (life expectancy judged to be less than 5 days).
• Patients with severe complications in the liver
• Pregnant or lactating women
• Patients who have received at least 5 days of prior systemic treatment of fluconazole or echinocandin with no response.
• Patients who have prior antifungal infection requiring treatment with systemic antifungal agents for conditions other than candidemia and invasive candidiasis.